$ORGS HUGE NEWS 🚨 Mainz Biomed Enrolls 1st Patient in eAArly DETECT 2 Study! 🚨
This 2,000-patient trial aims to validate its next-gen colorectal cancer (CRC) test, designed to detect advanced precancerous lesions and shift CRC screening toward prevention. 🧬
Top-line results expected Q4 2025, paving the way for the pivotal U.S. study in 2026. Big step toward eliminating CRC
$ORGS POCare model looks promising. Watching closely as Orgenesis navigates CGT landscape. Potential for disruption in cell therapy accessibility. Small position building. notable article: https://beyondspx.com/article/orgenesis-inc-otcqx-orgs-pioneering-decentralized-cell-and-gene-therapies-for-global-accessibility
$ORGS the bid size and ask size walls are fake.
Example: normal 500 share bid or ask would appear as “5”
Here it shows the actual size. Here 500 means 500 shares, not 50,000
$ORGS I would like to congratulate you on the remarkable move achieved today in the markets. It is a clear reflection of a solid strategy and vision, which undoubtedly inspires confidence in investors. $VTGN $HYPD
Wonderful move by $ORGS, recovering ground, let's see if it can sustain the rise in this market, for now we can look for more opportunities with solid fundamentals $VTGN looks like a good option to keep in mind for all the fundamentals it has.
